


Management of treatment-induced diarrhoea

This document refers only to the management of treatment induced diarrhoea.

*** For the management of diarrhoea in patients related to:**

- gastrointestinal graft versus host disease (GVHD) post Allogeneic Haemopoietic Stem Cell Transplant, refer to GVHD documents and refer to individual institutional policy.
- PD1 (eg. nivolumab and pembrolizumab), PDL-1 (eg. atezolizumab, avelumab and durvalumab) or CTLA4 (eg. ipilimumab) inhibitor related diarrhoea, refer to Management of immune related adverse events (irAEs) document.
- irinotecan based therapy see separate algorithm.



E: feedback@eviq.org.au W: eviq.org.au